These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 31132385)

  • 21.
    Jeong JH; Choi WS; Antigua KJC; Choi YK; Govorkova EA; Webby RJ; Baek YH; Song MS
    J Virol; 2020 Dec; 95(1):. PubMed ID: 33055248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low replicative fitness of neuraminidase inhibitor-resistant H7N9 avian influenza a virus with R292K substitution in neuraminidase in cynomolgus macaques compared with I222T substitution.
    Suzuki S; Shichinohe S; Itoh Y; Nakayama M; Ishigaki H; Mori Y; Ogata-Nakahara A; Nguyen CT; Okamatsu M; Sakoda Y; Kida H; Ogasawara K
    Antiviral Res; 2020 Jun; 178():104790. PubMed ID: 32272175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Substitution of I222L-E119V in neuraminidase from highly pathogenic avian influenza H7N9 virus exhibited synergistic resistance effect to oseltamivir in mice.
    Tang J; Gao R; Liu L; Zhang S; Liu J; Li X; Fang Q; Feng Z; Xu C; Huang W; Wang D
    Sci Rep; 2021 Aug; 11(1):16293. PubMed ID: 34381119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
    Gubareva LV; Trujillo AA; Okomo-Adhiambo M; Mishin VP; Deyde VM; Sleeman K; Nguyen HT; Sheu TG; Garten RJ; Shaw MW; Fry AM; Klimov AI
    Antivir Ther; 2010; 15(8):1151-9. PubMed ID: 21149922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility.
    Hai R; Schmolke M; Leyva-Grado VH; Thangavel RR; Margine I; Jaffe EL; Krammer F; Solórzano A; García-Sastre A; Palese P; Bouvier NM
    Nat Commun; 2013; 4():2854. PubMed ID: 24326875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutations at the monomer-monomer interface away from the active site of influenza B virus neuraminidase reduces susceptibility to neuraminidase inhibitor drugs.
    Fujisaki S; Imai M; Takashita E; Taniwaki T; Xu H; Kishida N; Yokoyama M; Sato H; Tashiro M; Odagiri T
    J Infect Chemother; 2013 Oct; 19(5):891-5. PubMed ID: 23529501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance profiles for the investigational neuraminidase inhibitor AV5080 in influenza A and B viruses.
    Ivashchenko AA; Jones JC; Shkil DO; Ivanenkov YA; Pascua PNQ; Penaflor MK; Karapetian RN; Govorkova EA; Ivachtchenko AV
    Antiviral Res; 2023 Sep; 217():105701. PubMed ID: 37567255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unique Determinants of Neuraminidase Inhibitor Resistance among N3, N7, and N9 Avian Influenza Viruses.
    Song MS; Marathe BM; Kumar G; Wong SS; Rubrum A; Zanin M; Choi YK; Webster RG; Govorkova EA; Webby RJ
    J Virol; 2015 Nov; 89(21):10891-900. PubMed ID: 26292325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influenza A viruses of swine circulating in the United States during 2009-2014 are susceptible to neuraminidase inhibitors but show lineage-dependent resistance to adamantanes.
    Baranovich T; Bahl J; Marathe BM; Culhane M; Stigger-Rosser E; Darnell D; Kaplan BS; Lowe JF; Webby RJ; Govorkova EA
    Antiviral Res; 2015 May; 117():10-9. PubMed ID: 25701593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.
    Okomo-Adhiambo M; Nguyen HT; Sleeman K; Sheu TG; Deyde VM; Garten RJ; Xu X; Shaw MW; Klimov AI; Gubareva LV
    Antiviral Res; 2010 Feb; 85(2):381-8. PubMed ID: 19917319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus.
    Pizzorno A; Abed Y; Bouhy X; Beaulieu E; Mallett C; Russell R; Boivin G
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1208-14. PubMed ID: 22203589
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Substitutions at H134 and in the 430-loop region in influenza B neuraminidases can confer reduced susceptibility to multiple neuraminidase inhibitors.
    Mohr PG; Williams J; Tashiro M; Streltsov VA; McKimm-Breschkin JL
    Antiviral Res; 2020 Oct; 182():104895. PubMed ID: 32750469
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Competitive fitness of influenza B viruses with neuraminidase inhibitor-resistant substitutions in a coinfection model of the human airway epithelium.
    Burnham AJ; Armstrong J; Lowen AC; Webster RG; Govorkova EA
    J Virol; 2015 Apr; 89(8):4575-87. PubMed ID: 25673705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Computational assay of H7N9 influenza neuraminidase reveals R292K mutation reduces drug binding affinity.
    Woods CJ; Malaisree M; Long B; McIntosh-Smith S; Mulholland AJ
    Sci Rep; 2013 Dec; 3():3561. PubMed ID: 24356381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. R229I substitution from oseltamivir induction in HA1 region significantly increased the fitness of a H7N9 virus bearing NA 292K.
    Tang J; Zou SM; Zhou JF; Gao RB; Xin L; Zeng XX; Huang WJ; Li XY; Cheng YH; Liu LQ; Xiao N; Wang DY
    Emerg Microbes Infect; 2024 Dec; 13(1):2373314. PubMed ID: 38922326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of R152K and R368K neuraminidase catalytic substitutions on in vitro properties and virulence of recombinant A(H1N1)pdm09 viruses.
    Tu V; Abed Y; Fage C; Baz M; Boivin G
    Antiviral Res; 2018 Jun; 154():110-115. PubMed ID: 29674164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of influenza B viruses with reduced susceptibility to influenza neuraminidase inhibitors.
    Brown SK; Tseng YY; Aziz A; Baz M; Barr IG
    Antiviral Res; 2022 Apr; 200():105280. PubMed ID: 35304163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor.
    Wu Y; Gao F; Qi J; Bi Y; Fu L; Mohan S; Chen Y; Li X; Pinto BM; Vavricka CJ; Tien P; Gao GF
    J Virol; 2016 Dec; 90(23):10693-10700. PubMed ID: 27654293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peramivir susceptibilities of recombinant influenza A and B variants selected with various neuraminidase inhibitors.
    Fage C; Tu V; Carbonneau J; Abed Y; Boivin G
    Antivir Ther; 2017; 22(8):711-716. PubMed ID: 29082897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuraminidase inhibitor susceptibility and neuraminidase enzyme kinetics of human influenza A and B viruses circulating in Thailand in 2010-2015.
    Tewawong N; Marathe BM; Poovorawan Y; Vongpunsawad S; Webby RJ; Govorkova EA
    PLoS One; 2018; 13(1):e0190877. PubMed ID: 29324781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.